Option Care Health, Inc. Common Stock
OPCHOption Care Health, Inc. (OPCH) is a leading provider of home and alternate site infusion services in the United States. The company offers a wide range of infusion, pharmacy, and respiratory therapy services for patients with chronic, acute, and specialty conditions. It primarily serves insurance companies, pharmacy benefit managers, and healthcare providers, supporting patient care outside traditional hospital settings.
Company News
Option Care Health, the nation's largest independent provider of home and alternate site infusion services, announced the appointment of Robert Okunski as Vice President of Investor Relations effective May 26, 2026. Okunski brings over two decades of investor relations experience across healthcare, technology and energy sectors, and will lead the...
Law firm Kirby McInerney LLP is investigating Option Care Health for potential securities law violations following a significant stock price decline. The company issued optimistic guidance in February 2026 but missed Q1 earnings expectations in April, causing shares to drop 24%. The firm is seeking investors who purchased OPCH securities to discu...
Option Care Health (OPCH) shares fell approximately 26-30% after the company reported a Q1 2026 revenue miss and slashed full-year 2026 guidance by $125-225 million, down from $5.8-6.0 billion to $5.675-5.775 billion. The significant guidance cut came just two months after management reaffirmed the original guidance on the Q4 2025 earnings call. ...
Johnson Fistel, PLLP announced investigations into GE HealthCare Technologies, Option Care Health, and Rocky Brands on behalf of investors who suffered losses. GE HealthCare disclosed significantly reduced earnings guidance and a $250 million increase in expected input costs due to inflation, leading to a sharp stock price decline.
Option Care Health's stock fell over 30% on April 30, 2026, after the company reported weaker-than-expected first quarter results and cut full year revenue guidance due to a larger than anticipated patient census reset in its chronic inflammatory disease portfolio. Block & Leviton is investigating potential securities law violations and encouragi...
